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Abstract 
Bacteriophages (or phages) are naturally-occurring viruses that can infect and kill bacteria. They are 
remarkably diverse, numerous and widespread. Each phage has a narrow host range yet a large 
majority of bacteria studied so far play host to bacteriophages, hence the remarkable phage 
diversity. Phages were discovered just over 100 years ago and they have been used for treatment of 
bacterial infections in humans and other animals since the 1920s. They have also been studied 
intensively and this has led to, and continues to lead to, major insights in the fields of molecular 
biology and recombinant DNA technology, including that DNA is the genetic material, nucleotides 
are arranged in triplets to make codons, and messenger RNA is needed for protein synthesis. This 
article begins with a description of bacteriophages and explains why there has recently been a 
strong resurgence of interest in their clinical use for treatment of bacterial infections, particularly 
those caused by organisms resistant to multiple antimicrobial compounds. The history of 
bacteriophage therapy is briefly reviewed, followed by a review and critique of promising but very 
limited clinical research on the use of bacteriophages to treat bacterial infections in dogs. Other 
potential veterinary uses and benefits of bacteriophage therapy are also briefly discussed. There are 
important practical challenges that will have to be overcome before widespread implementation and 
commercialisation of bacteriophage therapy can be achieved, which are also considered. 
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Introduction 
Bacteriophages (or phages) are viruses that can infect and kill bacteria. They are remarkably 
diverse, numerous and widespread in nature. Phages were discovered just over 100 years ago and 
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have been used for treatment of bacterial infections in humans and other animals since the 1920s. 
After penicillin became widely available, interest in bacteriophage therapy waned substantially in 
much of the western world but continued elsewhere, especially in some East European countries.  
The emerging antimicrobial resistance crisis has caused a resurgence of interest in bacteriophage 
therapy. Bacteriophages can kill their host bacteria regardless of whether or not the host is resistant 
to multiple antimicrobial compounds. There has recently been a marked increase in the number and 
quality of research publications dealing with phage therapy. A few of these publications have dealt 
with clinical trials of a phage preparation for treatment of Pseudomonas aeruginosa otitis externa in 
dogs. However there are important challenges that will need to be overcome if bacteriophage 
therapy is to become a mainstream treatment modality that is used widely. 
The purpose of this article is to provide veterinary practitioners, particularly companion animal 
practitioners, with basic knowledge and understanding of bacteriophage therapy, including some of 
the challenges to its use, so that they are in a stronger position to consider its use in their patients 
when future opportunities arise. 
What are bacteriophages? 
Bacteriophages  are viruses that parasitise prokaryotes, including bacteria. They were discovered a 
little over 100 years ago and some of them were studied intensively from the 1940s onwards, 
contributing substantially to developments in the fields of molecular biology and recombinant DNA 
technology. Virulent (or lytic) bacteriophages can infect, lyse and kill bacteria, including pathogens 
of veterinary importance that are resistant to multiple antimicrobial compounds. Immediately after 
infection, the bacterial cellular machinery is redirected to manufacture of phage particles, which are 
released in large numbers when the host cell lyses. These newly-formed virus particles are then 
available to infect additional bacterial cells. The typical structure of a T4 phage (often used in 
therapy) and the T4 lytic infection cycle are presented in Figure 1. Electron micrographs of five 
phages isolated from a sewage treatment plant (in Palmerston North, NZ) that were able to kill a 
broad range of canine and feline uropathogenic Escherichia coli (UPEC) strains are shown in 
Figure 2. Bacteriophages have been used to treat bacterial infections in animals and humans since 
the early 1920s (Sulakvelidze et al. 2001). In view of the emerging and worsening global 
antimicrobial resistance crisis (Van Puyvelde et al. 2018), bacteriophage therapy as an alternative or 
supplement to conventional antimicrobial therapy has received renewed attention in recent years 
(Golkar et al. 2014; Grant et al. 2016). 
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Bacteriophages are extremely diverse, numerous and widespread. Their origins are very probably 
ancient (Hatfull and Hendrix 2011). Almost every bacterial species that has been studied in 
sufficient detail has been found to host at least one kind of bacteriophage, often many. Most 
bacteriophages are host strain-specific, explaining (together with ancient ancestry) their 
extraordinary diversity (Hatfull 2015).  Phage particles are also hugely abundant in the external 
environment. For example, it has been estimated that coastal seawater contains approximately 107 
tailed phage particles per mL (Wommack and Colwell 2000). Sewage-polluted rivers probably 
contain far higher concentrations. The number of phage particles on Earth at any instant is estimated 
at 1031; an astronomically huge figure. There is also massive turnover (1023 phage infections per 
second) of this population (Hatfull and Hendrix 2011). 
Bacteriophages have been used as tools and studied extensively in the development of molecular 
biology and recombinant DNA technology. Just some of the discoveries made through study of 
phages include DNA being the genetic material (except in RNA viruses); nucleotides are arranged 
in triplets to form codons; messenger RNA is needed for protein synthesis; and restriction 
endonucleases, which arose in bacteria during the course of evolution to cleave infecting 
bacteriophage DNA, can be used as workhorses by researchers and technologists in recombinant 
DNA work (Salmond and Fineran 2015). The study of bacteriophages continues to yield remarkably 
useful and exciting insights and new tools. Recently this includes tools derived from the bacterial 
immune system, or CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), which 
act against phages and plasmids (Uppada et al. 2018). These tools are now being used extensively 
for editing the genomes of many plants and animals, including, potentially, humans and companion 
animals (Lee et al. 2018).  
The diversity of phages is as impressive as their massive abundance. Their diversity mirrors, indeed 
seems to exceed, that of their host bacteria and members of Archaea. In one small study, a single 
visit to a sewage treatment plant in Palmerston North, NZ, and collection of a small volume of 
effluent fluid, was sufficient to discover 40 distinct bacteriophages capable of killing canine and 
feline uropathogenic Escherichia coli (UPEC) strains (Freitag et al. 2008). The mean proportion of 
UPEC strains that could be killed by an individual bacteriophage was 21/53 (40 (min 17, max 
72)%). Only 3/53 of the studied UPEC strains could not be killed by any of the phages that were 
collected during that single collection visit. The 10 most effective phages could each, individually, 
kill >50% of the 53 studied UPEC strains. Used in combination, i.e. in a phage cocktail, as might be 
used clinically, these 10 phages could be expected to kill up to 92% of the studied UPEC strains.  
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There is remarkable diversity in phage biology. It is very likely that collection of effluent fluid from 
a much larger sewage treatment facility (for example, in a much larger city), or perhaps repeated 
visits to a small facility, would have provided correspondingly greater phage diversity. Related to 
this supposition, it was reported as early as 1896 that water drawn from the Ganges and Jumna 
rivers in India had marked antimicrobial activity, specifically, against Vibrio cholerae (Hankin 
1896). Hankin found that the antimicrobial factor or substance passed through fine porcelain filters 
and was variably heat-labile. These findings have been interpreted by many subsequent authors as 
early evidence of bacteriophage activity, although authors of a recent detailed analysis have 
disputed this interpretation (Abedon et al. 2011b). 
Why is there resurgent interest in the use of bacteriophage therapy? 
Emerging and worsening antimicrobial resistance, which has recently driven a resurgence of 
interest in bacteriophage therapy, represents an enormous threat to public health; one that is 
exacerbated by an almost empty antimicrobial pipeline (Burki 2017). The implications of this threat 
for New Zealand has been reviewed by the Royal Society of New Zealand – Te Apārangi 
(Anonymous 2017). The global cost of this worsening crisis is reportedly high and growing, 
although reliable estimates are difficult to obtain. A systematic literature review of reports on the 
economic burden caused by antimicrobial resistance was recently published (Naylor et al. 2018). 
This article reported an economic burden ranging from US$21,832 per case to a decrease in global 
gross domestic product (GDP) of  >US$3 trillion (in 2013 dollars) by 2050.  
Multiple, potential coping strategies for worsening antimicrobial resistance have been proposed. 
Among these bacteriophage therapy has received relatively little, but increasing, attention. A key 
point is that bacteriophages can infect and kill their bacterial hosts regardless of whether or not the 
hosts are resistant to multiple antimicrobial compounds. This is because antimicrobial resistance 
and phage susceptibility are, for the most part, unrelated. In general, antimicrobial resistant bacteria 
are no less susceptible to phage killing (Allen et al. 2017). Indeed, one recent paper indicates that, 
at least for one bacterial host species (Acinetobacter baumannii), antimicrobial resistant bacteria 
were more susceptible to phage killing than antimicrobial susceptible strains (Chen et al. 2017). 
Although the worsening antimicrobial resistance crisis has strengthened recent interest in 
bacteriophage therapy, there are many other infectious disease situations, beyond the treatment of 
antimicrobial-resistant infections, for which phage therapy holds promise. For example, a key, 
potential advantage is that bacteriophages multiply at the site of a bacterial infection. Difficult-to-
access infections may therefore be more amenable to bacteriophage therapy than to antimicrobial 
therapy, if a sufficient number of phage particles can initially be applied to, or gain access to, the 
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site of infection (Payne et al. 2000). Phage particles are much larger than antimicrobial molecules, 
so ensuring they gain access to the sites of infection can be a substantial challenge, as discussed in 
detail in one recent review (Nilsson 2014). The exquisite host specificity of bacteriophages (Freitag 
et al. 2008; Jensen et al. 2015) is another important potential advantage. Non-pathogenic and 
potentially health-promoting bacteria in the normal microbiome are likely to be spared because of 
this (Miller-Ensminger et al. 2018). Indeed, the host specificity is often so extreme as to require use 
of mixtures of several different phages (phage cocktails) to treat infections (Freitag et al. 2008; 
Melo et al. 2016). More sophisticated approaches to the development of expanded-range phage 
mixtures have been developed recently (Mapes et al. 2016). 
Purified phage preparations have been safely administered to humans topically, orally, 
intravenously and into body cavities (Brussow 2016; Sarker et al. 2016; Speck and Smithyman 
2016). Phages and phage subcomponents have also been sprayed onto food products (Galarce et al. 
2014), including pet foods (Heyse et al. 2015), to increase food safety. This is a preventative rather 
than a therapeutic use of phages and therefore will not be considered further in this review.  
A brief history of bacteriophage therapy 
The history of phage therapy has been previously reviewed (Summers 2001; Chanishvili 2012; 
Wittebole et al. 2014). Bacteriophages were discovered about 100 years ago, independently, by 
Twort in London in 1915 and d’Herelle in Paris, in 1917 (Summers 2011). Twort described “glassy 
transformation” of his micrococcal colonies. Today, when phages are grown on a lawn of bacteria 
on agar, the clear spots caused by focal bacterial lysis are called plaques as shown in Figure 3. Soon 
after he made his discovery, d’Herelle began to investigate the use of bacteriophages for treatment 
of infectious diseases of animals. He studied pasteurellosis in water buffaloes, salmonellosis in 
chickens and shigellosis in rabbits (Summers 2001). Having established to his own satisfaction their 
safety and promising efficacy, he went on to carry out human trials. D’Herelle’s first research report 
on phage therapy in humans, published in 1921, described success in the treatment of bacillary 
dysentery in children. He later reported apparent success in the treatment of bubonic plague, using 
direct injection of a bacteriophage preparation into the buboes (infected lymph nodes). Remarkably, 
bacteriophages from d’Herelle’s original, start-up company remained commercially available to 
French physicians until 1978. Bacteriophage therapy continued to be available and used clinically in 
France until the early 1990s (Abedon et al. 2011a). 
Early progress in developing efficacious bacteriophage preparations was hampered by a deep lack 
of understanding of phage biology. Early on, many researchers believed that bacteriophages were 
enzymes rather than viruses (Summers 2001). Some commercially-available preparations contained 
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preservatives that would undoubtedly have inactivated, and therefore rendered ineffective, the 
phages. Later on, the fact that much of the work on bacteriophage therapy was being done in the 
Union of Soviet Socialist Republics (USSR) gave bacteriophage therapy a so-called Soviet Taint in 
western Europe and North America (Summers 2001). 
In the 1940s, the increasing clinical use of penicillin, and appreciation of its dazzling efficacy, led 
to a substantial decline of interest in bacteriophage therapy, particularly in the United States of 
America and United Kingdom. Phage therapy continued to be studied and used extensively in 
France, Germany, Russia and the rest of Eastern Europe (Summers 2011). 
Throughout the 1980s, excellent veterinary research on phage therapy was carried out by Smith and 
his colleagues at the Houghton Institute for Animal Disease Research (UK). He studied the 
therapeutic use of bacteriophages in young farm animals, mostly directed against bacterial 
diarrhoeal diseases (Smith and Huggins 1982, 1983; Smith et al. 1987a). This work addressed many 
of the weaknesses of earlier experimental studies of bacteriophage therapy. In a set of landmark 
studies, these researchers investigated the use of phage therapy in calves, piglets and lambs. They 
also carried out rigorous experimental studies in mice. They focussed upon treatment of diarrhoea 
caused by a particular, well characterised strain of E. coli. In 1987 they showed that severe, 
experimental diarrhoea in calves could be cured by a single dose of 105 phage particles and could be 
prevented by doses as low as 100 particles (Smith et al. 1987b). They obtained their phages from 
ordinary sewage. 
Little was published about bacteriophage therapy in the 1990s in journals indexed by Medline 
(https://www.ncbi.nlm.nih.gov/pubmed/). However from 2000–2010 numerous publications 
considered a range of topics including use of bacteriophage therapy in the management of 
antimicrobial resistant infections (Biswas et al. 2002); use of bacteriophages to “cleanse” farm 
animals of potentially zoonotic infections in the immediate pre-slaughter period, i.e. before 
transportation of the animals to the abattoir (Loc Carrillo et al. 2005); and the use of bacteriophages 
or bacteriophage components to control foodborne bacteria in packaged food products (Greer 
2005).  Since 2009 a much larger number of articles, covering a remarkably broad range of 
bacteriophage therapy-related topics, has been published each year in journals indexed by Medline 
and Web of Science (https://clarivate.com/products/web-of-science/).  
Recent studies of bacteriophage therapy in companion animals 
There is an excellent and growing literature on the use of bacteriophages in livestock, particularly 
intensively-reared livestock, to improve food safety and diminish the use of antimicrobials (e.g. 
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Endersen et al. 2014 and Kazi and Annapure 2016). In comparison to livestock, very little research 
has so far been published on the use of bacteriophages in companion animals. The author is aware 
that bacteriophage therapy has occasionally been used by companion animal and equine 
practitioners on an exceptional basis but, so far, very few research or clinical publications are to be 
found. 
There have, however, been a few promising, recent developments and publications on phage 
treatment of P. aeruginosa otitis externa, including in dogs (Wright et al. 2009; Hawkins et al. 
2010). Indeed, a commercial veterinary product for treatment of Pseudomonas otitis (containing six 
bacteriophages) became available in Europe as a consequence of some of this research, although it 
is not currently available. The following paragraphs describe this small body of research on phage 
therapy in dogs. 
The first, preliminary paper, published in 2006, provided two very brief case reports: a human with 
skin burns and P. aeruginosa-infected, failing skin grafts and a dog with chronic otitis externa 
(Marza et al. 2006). The dog was a 5-year-old St Bernard, reported to have atopy and chronic, 
bilateral otitis externa, associated with P. aeruginosa infection. The otitis had failed to resolve 
despite repeated courses of topical and systemic antimicrobials. A bacteriophage preparation was 
applied topically to both patients. Substantial multiplication of the applied Pseudomonas-targeting 
bacteriophage (as surrogate evidence of bacterial killing) was noted in both patients shortly after 
topical treatment, much more impressive in the dog. Little clinical detail and no information about 
the phages used are provided in this first paper. The dog’s right ear was treated, and was reported to 
be dramatically improved 27 hours after the bacteriophage application with no adverse 
consequences. Then the other ear was treated. The bacteriophage used in this dog multiplied at least 
a million-fold in the right ear shortly after it was administered. P. aeruginosa was subsequently 
isolated from the ears of this dog in the weeks after bacteriophage treatment and there were cycles 
of clinical improvement and deterioration. However the ears were reported to be consistently better 
than before the bacteriophage treatment and no further antimicrobial treatment was used. Nine 
months after phage application, both ears were described as having completely recovered and P. 
aeruginosa was not subsequently cultured. It is not stated how many samples were collected for 
culture and sensitivity. 
A second study of bacteriophage therapy for chronic, P. aeruginosa-associated otitis externa in 
dogs was published 4 years later by members of the same British research group (Hawkins et al. 
2010). Ten dogs with P. aeruginosa-associated otitis externa each received, into one of their 
external auditory canals, a 0.2 mL cocktail of six bacteriophages, 100,000 plaque-forming units of 
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each phage in the mixture. The chosen combination of six bacteriophages had previously been 
shown to have in vitro activity against 90% of P. aeruginosa strains derived from canine otitis 
externa cases. The total number of strains examined to obtain this percentage figure is not stated in 
the paper. Dogs were re-examined 48 hours after a single bacteriophage treatment. A clinical score, 
quantitative bacterial culture and bacteriophage quantitation were done before and after the 
treatment. There was a 30% mean reduction in clinical score at 48 hours, a 67% reduction in 
bacterial count, and a 99.1-fold mean increase in bacteriophage count. Limited information is 
provided about which particular bacteriophages (of the six different types in the cocktail) had 
increased in number in each dog and whether the effective phage or phages differed from dog to 
dog, as one might expect. It is noteworthy that the phage cocktails used in each dog were not 
optimised for each particular dog. A standard product was used, presumably with a view to rapid 
commercialisation. Indeed, a commercial veterinary product was successfully developed out of this 
research. Much better results might have been anticipated if phage cocktails tailored to the 
particular P. aeruginosa strains infecting each dog had been used. However, as will be discussed 
below, that would have made registration of a commercial product much more challenging, if not 
impossible. It would be interesting to know whether in vitro susceptibility of bacteria to the phage 
cocktail was tested in these dogs and whether or not in vitro results correlated with in vivo clinical 
improvement of the dogs. 
Although there were limitations in the design and execution of these two veterinary studies, the 
results were sufficient to support the licensing of a commercial product in Europe, and these 
findings are very promising. It would be interesting to compare such a fixed ingredient product with 
personalised phage therapy, i.e. choosing and using the best phages for a particular infection on the 
basis of in vitro susceptibility of bacteria. 
This research group also carried out a randomised, double-blind, placebo-controlled, phase I/II 
clinical trial of a therapeutic bacteriophage preparation for use in humans, similar to the cocktail 
used in the previously described study of canine otitis (Wright et al. 2009). This clinical trial was 
for treatment of chronic otitis due to antimicrobial-resistant P. aeruginosa in humans. This was the 
first clinical trial of its kind. 
What challenges are impeding the widespread adoption and implementation of 
bacteriophage therapy? 
Many challenges will need to be overcome if bacteriophage therapy is to become a mainstream, 
commercially-viable therapeutic option for humans and companion animals with difficult-to-
manage bacterial infections rather than remaining a therapeutic modality used only piecemeal or in 
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the worst of clinical circumstances. Some of these challenges are unfortunately formidable. As a 
consequence, many researchers and companies have turned away and focussed their attention on 
non-therapeutic uses of bacteriophages such as in food safety, nutraceutical development and 
clinical diagnostics (Lu and Koeris 2011). However the growing antimicrobial resistance crisis is 
also formidable, therefore some researchers and companies are continuing their efforts to address 
challenges in several distinct areas. 
The challenge of insufficient high-quality evidence 
There is a pressing need for further well-controlled clinical trials of bacteriophage therapy to be 
completed in humans and companion animals and the results published. Data from experimental 
animal studies (Biswas et al. 2002; Shivaswamy et al. 2015), and a considerable volume of 
published clinical experiences, mostly from Eastern Europe, support the view that bacteriophage 
therapy can be highly efficacious under a variety of circumstances, including when treating serious 
bacterial infections caused by organisms resistant to multiple antimicrobial compounds (Verstappen 
et al. 2016). On the other hand, in vitro susceptibility to phage is not always a reliable predictor of 
in vivo efficacy (Tsonos et al. 2014). Considerably more robust evidence is required. 
The challenge of meeting regulatory requirements 
Existing medicinal regulatory frameworks are designed to deal with ready-to-use pharmaceutical 
and biological products. Fixed-ingredient phage cocktails containing, for example, equal numbers 
of six different phages against a particular strain or species of pathogenic bacteria, although quite 
different from conventional pharmaceutical compounds, are somewhat reminiscent of modified live 
vaccines or medical products that contain more than one active ingredient. Every animal treated 
with such a phage remedy would receive the same product. As described above, one phage-
containing medicinal product has already been successfully licensed for veterinary use in Europe 
(Hawkins et al. 2010).  
Personalised phage therapy is radically different. Each animal would potentially receive a unique 
cocktail, based on the demonstrated phage susceptibility of the infecting bacterial pathogen(s) 
causing illness. This is already happening on a very small scale in  the worst of clinical 
circumstances in humans and companion animals (Fish et al. 2018). How will such phage-based 
medicinal products be defined and regulated? Fauconnier (2017) has described them as being 
“...somewhere between magistral formulas and industrially made medicinal products”. Considerable 
challenges will need to be overcome before widespread implementation is achieved. Indeed, a new 
paradigm for management of bacterial infectious diseases will need to be developed, beginning 
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when a bacterial pathogen is isolated from a diseased individual, identified and determined to be 
resistant to multiple antimicrobial compounds (Chan et al. 2013).  
Expert working groups in Europe and the United States of America have already done some of the 
work of scrutinising pharmaceutical regulatory frameworks with a view to identifying and tackling 
bottlenecks and potential tangles and finding ways forward to facilitate widespread implementation 
of personalised phage therapy (Huys et al. 2013; Pelfrene et al. 2016; Fauconnier 2017).   
The challenge of generally narrow phage host ranges 
Narrow host range of most phages can be viewed as both a challenge and a benefit, as previously 
discussed. The traditional approach to narrow phage host ranges has been to use phage cocktails 
rather than individual phages (Chan et al. 2013). Newer approaches include genetic modification of 
phages to broaden their host range and co-incubation of phages with multiple bacterial strains, 
including their cognate host, and selection of phage mutants that develop broadened host range 
(Mapes et al. 2016). 
An interesting question is “How many different phages should be in a cocktail”? The vast majority 
of reports describe cocktails that contain four to eight different phages, but this author was unable to 
find reasons, other than the following of historical precedent, why the number should not be much 
greater.  
The challenge of emerging bacterial resistance  
Bacteria have co-evolved with phages for hundreds of millions of years, so it is unsurprising that 
they have evolved multiple resistance mechanisms. Conversely, phages have evolved great diversity 
and a multiplicity of attack mechanisms. It has been reported that the use of phage cocktails tends to 
slow the emergence of bacterial resistance as compared with the use of individual phages (Fischer 
et al. 2013; Yu et al. 2017). Phages act synergistically when used in cocktails (Schmerer et al. 
2014). The enormity of phage diversity  would usually permit different individual phages, or even 
different phage cocktails, to be used sequentially in personalised treatment, should this prove 
necessary because of lack of effectiveness or emergence of resistance in particular patients. 
Challenges related to adverse clinical effects of phage therapy 
Concerns have been expressed that massive and rapid lysis of bacterial cells during phage therapy 
could occasionally be associated with rapid release of endotoxins, including superantigens, causing 
significant morbidity (Matsuda et al. 2005). However clinical descriptions of this potential adverse 
effect of phage therapy are not readily available. Still, animal experiments have shown that lysis-
deficient phages can be used in serious infections, such as severe septic peritonitis, and their use 
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was associated with lower mortality than was seen when using a conventional, lytic phage for 
treatment (Matsuda et al. 2005). Lysis-deficient phages kill bacteria without inducing endotoxin 
release. 
Poorly-manufactured phage preparations can also be contaminated with endotoxin, with the 
potential to cause morbidity, especially when delivered by nebuliser. Modern manufacturing 
techniques are available to prevent this (Cooper et al. 2014). 
Challenges associated with rapid removal of phage by the immune system, especially from 
the bloodstream 
Therapeutically applied bacteriophages are exposed to, and stimulate, the immune system of the 
animal under treatment (Krut and Bekeredjian-Ding 2018). This can produce a synergistic 
beneficial effect, with the immune system (particularly phagocytes) enhancing the ability of phage 
to resolve the infection (Roach et al. 2017). When phages are administered intravenously, many are 
removed rapidly by the reticuloendothelial system and phage-neutralising antibodies. Serial passage 
of phages through animals, and consequent selection of progressively longer-circulating mutants, 
has been achieved by researchers (Merril et al. 1996). 
Challenges associated with the potential for harmful gene transfers 
Some phages are capable of transmitting potentially harmful genes to their bacterial hosts. This 
matters if the bacterial cell does not die (i.e. is not lysed) immediately after phage infection. Some 
phages (described as temperate) can integrate into the host bacterial chromosome after infecting the 
cell and may bring toxin-encoding genes with them. The process is termed lysogeny and the phage 
is said to have entered the lysogenic lifecycle (Feiner et al. 2015). The process is reminiscent of 
retroviral integration into a vertebrate cell, in that the integrated phage genome is transmitted to 
subsequent generations of bacteria without being transcribed or translated and it does not cause 
bacterial cell lysis. At a later time the integrated phage genome ceases to be repressed, exits the 
lysogenic lifestyle, is expressed to make numerous viral particles and causes cell lysis. It is said to 
have entered the lytic cycle. 
The use of only virulent (rapidly lytic) phages for therapeutic purposes, not those prone to undergo 
lysogeny, reduces the risk of harmful horizontal gene transfer substantially (Hobbs and Abedon 
2016). Currently, bacteriophages intended for inclusion in any new commercial phage therapy 
product for use in humans, either in isolation, or as part of a cocktail, would need to be thoroughly 
characterised and safety tested to satisfy regulatory authorities. This would typically require full 
genome sequencing of each phage with a search for potentially deleterious genetic components, 
especially genes that encode toxins or bacterial virulence factors or predispose towards lysogeny. 
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Conclusion 
Bacteriophage therapy may, in future, prove to be a valuable component in a multi-pronged 
approach to dealing with the worsening challenge of increasing antimicrobial resistance in bacterial 
pathogens. However more evidence from high-quality clinical trials will be needed to increase 
confidence in the breadth of their effectiveness, and regulatory frameworks for licensing biological 
therapeutic agents will probably need to be reconsidered and adjusted if personalised phage therapy 
is to be approved for use beyond the worst clinical circumstances.   
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Figure 1. Anatomy and lytic infection cycle of phage T4. The phage DNA genome is initially 
within the icosahedral head. After attachment of the phage to the bacterial cell via its fibres 
(1), the tail shortens and phage DNA is injected into the bacterium (2). There, it is rapidly 
transcribed and translated to produce numerous new phage components (3). These 
autoassemble (4) and the cell lyses, releasing phage into the extracellular space (5). 
Image by Guido4 
(https://commons.wikimedia.org/wiki/File:11_Hegasy_Phage_T4_Wiki_E_CCBYSA.png) 
licensed under CC by SA 4.0 (accessed 3 June 2018).  
 
 
Figure 2. Electron micrographs of five phages collected in Palmerston North, New Zealand, 
that each had a relatively broad host range against uropathogenic Escherichia coli (Uranyl 
acetate staining, bar=100nm). The four on the left appear morphologically similar to lytic 
phage T4, widely used in phage therapy. The morphological findings were verified by DNA 
sequence analysis (Freitag et al. 2008). Image courtesy of Dr Thurid Johnstone, University 
of Melbourne, Australia. 
 
 
Figure 3. Photograph of phage plaques growing in soft agar on a lawn of their host bacteria. 
They appear clear, glassy, dark and circular. These are ΦM12 phages, but phages used for 
therapy appear similar.  
Image by Ninjatacoshell 
(https://upload.wikimedia.org/wikipedia/commons/0/08/%CE%A6M12_Plaques_in_Sinorhizo
bium_meliloti.JPG) licensed under CC by SA 3.0 (accessed 3 June 2018). 
 
